Home > Products > Antibodies > Flow Cytometry (FACS) Antibodies

Anti-Human PCSK9 Recombinant Antibody (SAA0158) (HV275107)

Datasheet Share product Copy info

Anti-Human PCSK9 Recombinant Antibody (SAA0158)

Anti-Human PCSK9 Recombinant Antibody (SAA0158)

Price(USD): $

Spec:

50ug
100ug

Number:

Contact us

Overview
Images
References
Datasheet

Overview

Catalog No.	HV275107
Description	Anti-Human PCSK9 Antibody (SAA0158) [SAA0158] (HV275107) is a human monoclonal antibody detecting PCSK9 in FCM. Suitable for Human. Highlights ●Flow Cytometry — Validated for flow cytometry applications.
Species reactivity	Human
Applications	FCM
Host species	Human
Isotype	IgG2, lambda
Clone ID	SAA0158
Clonality	Monoclonal
Target	Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
Endotoxin level	Please contact with the lab for this information.
Purity	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q8NBP7
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Background	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha). 1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658 2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796 3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702 4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458 5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827 6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751
Note	For research use only.

Images

SDS-PAGE

SDS-PAGE for Anti-Human PCSK9 Antibody (SAA0158)

References

Datasheet

Anti-Human PCSK9 Recombinant Antibody (SAA0158).pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: support@abinScience.com

Distributor list

Anti-Human PCSK9 Recombinant Antibody (SAA0158)